Transcript for By the Numbers: Pfizer’s $15 billion payday
Now to the news from finds in the first drug maker along with its partner bio intact to receive US authorization for a company nineteen vaccine. Here's what's next by the numbers fifteen billion dollars us revenue advisor says it expects from its come in nineteen vaccine in 20/20 one based on existing contracts. And that's likely underestimated because the company now says it can produce two billion vaccine doses this year far above what's been contract did. That includes 200 million doses of Pfizer promises for the US by the end of may. 154. Million dollars was Pfizer's revenue from the company's nineteen vaccine in 20/20 that was just the early days of the roll out. Why are accepted zero federal government money into developing manufacturing and still the vaccine but it did enter a multi billion dollar advance purchase deal. With a child administration's operation warp speed. And finally took that fifteen billion of revenue into perspective. I Serb holdings six and a half billion dollars from all of its vaccines in 20/20 so they're expected to more than triple. Those earnings gained 20/20 one and then of course Pfizer and by doing tech developed as highly effective vaccine in less than a year of feet than some expected. Could take as long as a decade.
This transcript has been automatically generated and may not be 100% accurate.